Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer

Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer

BackgroundLutetium-177 [177Lu]-PSMA-617 is a targeted radioligand that binds to prostate-specific membrane antigen (PSMA) and delivers radiation to metastatic prostate cancer. The presence of PSMA-negative/FDG-positive metastases can preclude patients from being eligible for this treatment. Biology-...

Full description

Bibliographic Details
Main Authors: Mathieu Gaudreault, David Chang, Nicholas Hardcastle, Price Jackson, Tomas Kron, Michael S. Hofman, Shankar Siva
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Oncology
Subjects:
BgRT
LuPSMA
theranostics
mCRPC
PSMA
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1134884/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1134884/full

Similar Items